banner image

EryDel Announces 6 Month Efficacy Results from Phase 3 ATTeST Trial


EryDel Announces 6 Month Efficacy Results from Phase 3 ATTeST Trial – 29th July 2021


The ATTeST trial was conducted in the United States, Europe, Asia, Australia, and Africa. 175 youngsters with an AT diagnosis aged 6 and over enrolled on the trial and were randomised to either high or low dose of EryDex (Dexamethasone Sodium Phosphate), or placebo treatment in a 1:1:1 ratio. The treatment duration was 6 months for the efficacy phase, then extended to 12 months for long term safety assessment.

The 6-month safety analysis has shown promising outcomes and demonstrated potential significant clinical benefit of EryDex in AT.  Additionally, the interim findings showed that EryDex was well tolerated in the trial participants and did not identify any alarming safety signals that might be expected with chronic steroid use.

This positive analysis gives hope that EryDex treatment could possibly offer future therapeutic intervention for many young people with AT.  However, whilst this is very positive news, the full results of the trial will be needed before next steps can be considered.

The final analysis after 12 months is due to be published in November 2021 and at that stage, we will hopefully have more information regarding potential efficacy of the treatment.

More details can be found by clicking here.